On Monday, Editas Medicine Inc (NASDAQ: EDIT) was 4.92% up from the session before settling in for the closing price of $2.44. A 52-week range for EDIT has been $0.91 – $5.09.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has dropped its sales by -1.48% annually for the last half of the decade. When this article was written, the company’s average yearly earnings per share was at 34.40%. With a float of $82.95 million, this company’s outstanding shares have now reached $83.71 million.
In an organization with 246 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 85.89%, operating margin of -590.68%, and the pretax margin is -805.8%.
Editas Medicine Inc (EDIT) Insider Updates
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Editas Medicine Inc stocks. The insider ownership of Editas Medicine Inc is 0.91%, while institutional ownership is 54.48%. The most recent insider transaction that took place on Jul 31 ’25, was worth 12,757. In this transaction EVP, CHIEF SCIENTIFIC OFFICER of this company sold 5,121 shares at a rate of $2.49, taking the stock ownership to the 64,398 shares. Before that another transaction happened on Jul 31 ’25, when Company’s Officer proposed sale 7,500 for $3.46, making the entire transaction worth $25,950.
Editas Medicine Inc (EDIT) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around 34.40% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 27.74% during the next five years compared to -1.48% drop over the previous five years of trading.
Editas Medicine Inc (NASDAQ: EDIT) Trading Performance Indicators
You can see what Editas Medicine Inc (EDIT) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 3.08. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 5.98.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.04, a number that is poised to hit -0.39 in the next quarter and is forecasted to reach -1.08 in one year’s time.
Technical Analysis of Editas Medicine Inc (EDIT)
Let’s dig in a bit further. During the last 5-days, its volume was 2.25 million. That was inferior than the volume of 3.0 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 10.27%.
During the past 100 days, Editas Medicine Inc’s (EDIT) raw stochastic average was set at 61.80%, which indicates a significant increase from 15.70% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.28 in the past 14 days, which was higher than the 0.19 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.39, while its 200-day Moving Average is $1.94.
